Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia

European Journal of Haematology

Volumn 75, Issue 4, 2005, Pages 355-358

  Tsironi, Maria ^a,b   Polonifi, K ^a   Deftereos, S ^a   Farmakis, D ^a   Andriopoulos, P ^a   Moyssakis, I ^a   Aessopos, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Department of Internal Medicine   (Greece)

Author keywords

Chelation; Heart failure; Hemosiderosis; Liver; Sickle thalassemia

Indexed keywords

CARDIAC GLYCOSIDE; CARVEDILOL; DEFERIPRONE; DEFEROXAMINE; DIGOXIN; FOLIC ACID; FUROSEMIDE; LACTULOSE; NEOMYCIN; SPIRONOLACTONE;

ADULT; ARTICLE; CASE REPORT; CHELATION THERAPY; DRUG CONTRAINDICATION; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEART FAILURE; HEMOSIDEROSIS; HUMAN; HUMAN CELL; IRON OVERLOAD; LIVER DYSFUNCTION; LONG TERM CARE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; THALASSEMIA; THALASSEMIA MAJOR; TRANSFUSIONAL HEMOSIDEROSIS; TREATMENT INDICATION;

ADULT; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; DEFEROXAMINE; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HEMOSIDEROSIS; HUMANS; LIVER FAILURE; MALE; PYRIDONES;

EID: 24744450965     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00528.x     Document Type: Article

References (16)

1. ANDERSON LJ, HOLDEN S, DAVIS B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-2179.
2. ANDERSON LJ, WESTWOOD MA, HOLDEN S, DAVIS B, PRESCOTT E, WONKE B, PORTER JB, WALKER JM, PENNELL DJ. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-355.
3. COHEN A, KRON E, BRITTENHAM G. Toxicity of transfusional iron overload in sickle cell anemia. Blood 1987;64:47a.
4. OLIVIERI NF. Progression of iron overload in sickle cell disease. Semin Hematol 2001;38:57-62.
5. SHAH FT, WESTWOOD MA, EVANS PJ, PORTER JB. Discordance in MRI assessment of iron distribution and plasma NTBI between transfusionally iron loaded adults with sickle cell and thalassemia. Abstract 2628. Blood 2002;100: ASH Meeting Abstracts.
6. COHEN A, PORTER JB. Transfusions and iron chelation therapy in thalassemia and sickle cell anemia. In: STEINBERG M., FORGET B., HIGGS D., NAGEL R., eds. Disorders of Haemoglobin. Cambridge: Cambridge University Press, 2001:979-1027.
7. AESSOPOS A, FARMAKIS D, HATZILIAMI A, FRAGODIMITRI C, KARABATSOS F, JOUSSEF J, MITILINEOU E, DIAMANTI-KANDARAKI E, MELETIS J, KARAGIORGA M. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004;73:359-366.
8. BORGNA-PIGNATTI C, RUGOLOTTO S, DE STEFANO P, PIGA A, DI GREGORIO F, GAMBERINI MR, SABATO V, MELEVENDI C, CAPPELLINI MD, VERLATO G. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998;850:227-231.
9. ATHANASSIOU-METAXA M, KOUSI A, HATZIPANTELIS E, TSATRA I, IKONOMOU M, PERIFANIS V, TSANTALI H. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded b-thalassemia patients. Haematologica 2004;89:ELT07.
10. KATTAMIS A, KASSOU C, BERDOUSI H, LADIS V, PAPASSOTIRIOU I, KATTAMIS C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica 2003;88:1423-1425.
11. ANDERSON LJ, WONKE B, PRESCOTT E, HOLDEN S, WALKER JM, PENNELL DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516-520.
12. CARTHEW P, SMITH AG, HIDER RC, DORMAN B, EDWARDS RE, FRANCIS JE. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94. Biometals 1994;7:267-271.
13. CECI A, BAIARDI P, FELISI M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-336.
14. KONTOGHIORGHES GJ, NEOCLEOUS K, KOLNAGOU A. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003;26:553-584.
15. TONDURY P, ZIMMERMANN A, NIELSEN P, HIRT A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 1998;101:413-415.
16. WANLESS IR, SWEENEY G, DHILLON AP, GUIDO M, PIGA A, GALANELLO R, GAMBERINI MR, SCHWARTZ E, COHEN AR. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100:1566-1569.